Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

News Conference News AHA 2019

Aspirin Discontinuation Safe, Effective Strategy in ACS Subset: TWILIGHT

Yael L. Maxwell

November 17, 2019

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

News Conference News AHA 2018

Study Lays Groundwork for Pivotal Trial of Impella CP for LV Unloading Before PCI

November 11, 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

November 05, 2018

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2014

Vorapaxar Safe in NSTE-ACS But Bleeding Risk Merits 6-Month Delay Before Noncardiac Surgery

Yael L. Maxwell

November 16, 2014

News Conference News AHA 2012

TRILOGY ACS Substudy: No Relationship Between Platelet Reactivity, Outcomes

November 04, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.